Cxbladder

The difference in cancer detection

Cxbladder - The difference in cancer detection

Cxbladder is a urine-based genomic biomarker test optimised for the detection and rule-out of bladder cancer in patients presenting with haematuria and those being monitored for recurrent disease. The test helps clinicians prioritise their time and clinical resources, optimise practice workflow, and improve the overall patient experience.

Primary Detection


Cxbladder Triage

Cxbladder Triage is a frontline diagnostic that helps to de-intensify clinical work-up in haematuria patients with a low probability of bladder cancer, reducing the need for referral and further invasive procedures. The tests analyses gene expression alongside information on known bladder cancer risk factors like age, gender and smoking history to help rule out patients with a low risk of disease.

Triage supports a new model for clinical practice and resource utilisation. This deployment model provides care to the greatest number of patients and offers clinically actionable information at the earliest point in the patient care pathway.


Cxbladder Detect

In cases of atypical cytology, equivocal cystoscopy and other instances of diagnostic ambiguity, Cxbladder Detect helps to resolve uncertainty, increasing overall detection accuracy, and reducing the likelihood of a missed tumour.

As a test designed to optimise practice workflow and efficiency, Detect enables the risk stratification of patients presenting with haematuria, de-intensifying clinical workup in those with a low probability of bladder cancer, while prioritising those who require immediate care.

Bladder Cancer Surveillance


Cxbladder Monitor

Cxbladder Monitor is a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in patients with a low risk of recurrence.

Monitor improves patient comfort and compliance with cancer surveillance and management regimes. When used consistently on a single patient, the test can provide an accurate snapshot of that patient’s progression through their follow up.

 

Browse our library of clinical publications.

 

Overview


The Cxbladder suite: 

  • Enables risk stratification and safe rule out, helping to de-intensify clinical workup in haematuria patients with a low probability of bladder cancer, while prioritising those who require immediate care.
  • Resolves diagnostic ambiguity, improving overall detection accuracy, and reducing the likelihood of a missed tumour.
  • Offers a non-invasive surveillance alternative that can reduce the burden of cystoscopy in suitable patients, improving comfort and compliance.


Cxbladder works at a molecular level, analysing five biomarker genes to detect the presence or absence of bladder cancer.

  • Reliable: Cxbladder delivers exceptional performance with 100% objectivity.
  • Clinically proven: Proven performance in over 20 peer-reviewed publications for primary detection and surveillance. Cxbladder has been used by over 4,400 urologists in more than 100,000 patients. In New Zealand the test is available to 75% of the population via public healthcare, and to all other residents through an e-commerce portal.
  • Covered by Medicare
  • Easy-to-use: Cxbladder’s unique urine sample collection system is non-invasive and easy-to-use.
  • In-home sampling: To streamline patient care we offer an in-home sampling service to both haematuria and surveillance patients in the US and New Zealand.

 

Browse our library of clinical publications.

Cxbladder is available in the following countries

  • Australia – Through Pacific Edge PTY Australia
  • New Zealand – Through Pacific Edge Diagnostics NZ
  • Singapore - Through Pacific Edge Diagnostics Singapore
  • United States – Through Pacific Edge Diagnostics USA
  • Israel - Through ProGenetics Ltd (Distribution Partner)
  • Argentina, Uruguay, Venezuela - Through SouthGenetics (Distribution Partner)
  • Vietnam - Through Transviet Service and Trading Company Ltd (Distribution Partner)
  • Philippines - Through Hi-Precision Diagnostics (Distribution Partner)
  • Malaysia - Through WellSpring Ltd (Distribution Partner)

For further information on Cxbladder, please visit: www.cxbladder.com


Browse our library of clinical publications.

 

Pacific Edge is responsible for the development and determination of the performance characteristics for Cxbladder. Because Cxbladder is a Laboratory Developed Test (LDT), Cxbladder has not been cleared or approved by the US Food and Drug Administration (FDA).